Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Yoshiaki Ohmura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1102-9402; OpenAlex author ID A5103237126. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarc… Co-author DOI 10.1007/s00595-026-03481-z↗
  2. [The Six Cases of Recurrence of Lung Metastasis after Radical Resection of Pancreatic Cancer Performed at Our Hospital]. Co-author PMID 36927912↗
  3. [A Long-Term Survival Case of Locally Advanced Unresectable Pancreatic Adenocarcinoma after Chemoradiotherapy and Conversion Surgery]. Co-author PMID 35045473↗
  4. [A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. Co-author PMID 31164541↗
  5. [The Treatment Outcomes of FOLFIRINOX for Unresectable and Recurrent Pancreatic Cancer]. Co-author PMID 29394764↗
  6. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience]. Co-author PMID 28133095↗
  7. [Pancreatic Cancer with Liver Metastasis Treated with Radical Surgery after Chemotherapy]. Co-author PMID 28133194↗
  8. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience]. Co-author PMID 26805364↗
  9. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. Co-author PMID 26805366↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yutaka Takeda · 9 shared papers, 2015–2026 · strength 0.87
  2. Yoshiteru Katsura · 9 shared papers, 2015–2026 · strength 0.87
  3. Takuya Sakamoto · 5 shared papers, 2016–2023 · strength 0.40
  4. Kohei Murata · 3 shared papers, 2017–2023 · strength 0.30
  5. Tadafumi Asaoka · 1 shared paper, 2026 · strength 0.28
  6. Hidetoshi Eguchi · 1 shared paper, 2026 · strength 0.28
  7. Yuichiro Doki · 1 shared paper, 2026 · strength 0.28
  8. Yoshifumi Iwagami · 1 shared paper, 2026 · strength 0.28
  9. Hidenori Takahashi · 1 shared paper, 2026 · strength 0.28
  10. Shigeyuki Tamura · 4 shared papers, 2015–2016 · strength 0.18
  11. 村田 幸平 · 1 shared paper, 2021 · strength 0.11
  12. Katsunori Matsushita · 1 shared paper, 2015 · strength 0.04
  13. Yasufumi Sato · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.